Key Highlights
- Q3 2026 IM8 Revenue reached $62.9 million, up 266% year-over-year, marking the seventh consecutive record quarter.
- September was the strongest month ever at $23.7 million revenue, representing an annualized run rate of approximately $284 million.
- Earliest customers acquired in Q1 2025 have returned approximately 4.1x their Acquisition cost in Gross Profit in under two years.
- The company reaffirmed FY 2026 total revenue guidance of $220-230 million and FY 2027 IM8 revenue guidance of $400 million or more.
Prenetics Global Limited (NASDAQ:PRE), the Parent Company of AI-native direct-to-consumer wellness Brand IM8 co-founded by Sir David Beckham, has reported its third quarter 2026 financial results, showing accelerating revenue growth and improving unit economics.
Q3 Revenue Performance
Total revenue was $64.1 million, up approximately 228% year-over-year and above the company's guidance range. IM8 revenue was $62.9 million, up approximately 266% year-over-year, marking the seventh consecutive record quarter. September was the brand's strongest month at $23.7 million, representing an annualized revenue run rate of approximately $284 million.
Cohort Economics
The 27,000 customers acquired in Q1 2025, IM8's first full quarter, have returned approximately 4.1x their acquisition cost in gross profit in under two years, exceeding the 3-to-1 benchmark used in subscription businesses. The next 91,000 customers are on pace to reach the 3-to-1 threshold in early 2027. Customer Acquisition Cost declined for the second consecutive quarter to approximately $285 on record acquisition spend.
Profitability and Cash Flow
The quarter showed Adjusted EBITDA loss of $12.7 million, or 20% of revenue, improved from 39% in Q2. Contribution Profit reached $30.6 million, representing a 48% Contribution Margin. Adjusted Free Cash Flow was positive at $4.1 million. Cash and current financial Assets stood at $111.5 million at September 30, 2026, up from $109.4 million at the end of June.
Raised Investment and Outlook
The company reaffirmed FY 2026 total revenue guidance of $220-230 million and FY 2027 IM8 revenue guidance of $400 million or more. Second-half 2026 Adjusted EBITDA loss is now expected at $30-35 million, up from the previously guided $8-12 million, reflecting increased investment in customer acquisition. The company cited a $1 billion commitment from General Catalyst supporting its Marketing investment.
Planned launches not included in guidance include IM8 Hydration in Q1 2027, Care Bears by IM8 in H1 2027, and retail and China entry by year-end 2027.

_11_19_2026_12_19_36_050792.jpg)



_11_19_2026_12_02_05_658284.jpg)
Please wait processing your request...